Sign in
First Results From a Phase 1B Multiple-Dose Study of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate (ABC) With Extended Durability
Pravin U. Dugel, MD
Annual Meeting Talks
2019
Pharmacokinetic Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 3 Archway Trial
Peter A. Campochiaro, MD
Updates from the Field
2021
Differences in Intravitreal Silicone Oil Following Multiple Bevacizumab, Ranibizumab, and Aflibercept Injections
John T. Thompson, MD
Category: AMD-Neovascular